^
Association details:
Biomarker:VHL mutation
Cancer:Glioblastoma
Drug:Welireg (belzutifan) (HIF-2α inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Neuroendocrine Tumor)
New
Title:

FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2a) Inhibitor WELIREG™ (belzutifan) for the Treatment of Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Excerpt:
WELIREG is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2a (HIF-2a) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Published date:
05/28/2021
Excerpt:
For non-RCC tumors, ORR was 80% (16/20; 1 CR) in pNETs and 32% (16/50; 1 CR) in CNS hemangioblastomas...Belzutifan demonstrates clinical benefit and has a favorable safety profile in patients with VHL disease–associated ccRCC, pNETs, and hemangioblastomas.
DOI:
10.1200/JCO.2021.39.15_suppl.4555
Trial ID: